• Novo Nordisk shares fell 4.4% following its Q2 2026 earnings report, which included a narrow sales miss for its oral Wegovy pill.
  • Investors expressed disappointment that an upgraded full-year outlook was not higher and reacted negatively to a trial setback for the next-generation obesity drug CagriSema.
  • The company continues to face intense competitive pressure from Eli Lilly in the burgeoning obesity drug market.